Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Technologies, Partek Partner on End-to-End Bioinformatics Workflow

NEW YORK ─ Partek said Thursday that it has entered into an agreement with Santa Clara, California-based Agilent Technologies to integrate its Partek Flow bioinformatics software with the Agilent Alissa Clinical Informatics platform, providing an end-to-end analysis workflow that is customizable for Agilent's customers.

According to St. Louis-based Partek, it has made available the Agilent pipeline for RNA-seq inside Partek Flow, enabling Agilent to resell Partek Flow software through the Agilent Alissa portal.

Financial and other terms of the agreement were not disclosed.

"As next-generation sequencing is more broadly adopted for clinical applications, our customers' software requirements are also expanding," Kevin Meldrum, vice president and general manager of Agilent's Genomics Division, said in a statement. "By integrating Partek Flow with the Agilent Alissa Clinical Informatics Platform, we will strengthen our overall offering to address diverse applications and workflows across the translational research to clinical testing continuum."

With the integration of the bioinformatics software and clinical informatics platform, Partek Flow automatically processes and analyzes data in the background, and then passes results to the Agilent Alissa Interpret platform where the results are combined into a report. The integration enables clinical decision support and the identification of genetic signatures of disease in the clinical setting, as well as secondary analysis and the use of visualization tools for both DNA and RNA applications, Partek said.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.